Postoperative complications in patients with rheumatoid arthritis using a biological agent – A systematic review and meta-analysis

Abstract Objectives. To evaluate, through a systematic review of the literature, the association between the use of biological disease-modifying antirheumatic drugs (bDMARDs) and surgical site infection (SSI) or wound healing delay after orthopedic surgery in patients with rheumatoid arthritis (RA). Methods. A systematic review of articles indexed in the Cochrane Library, PubMed, and Web of Science from 1992 to 2012 was performed. The search aimed to identify studies describing SSI or wound healing delay in patients with RA treated with or without bDMARDs. Articles fulfilling the predefined inclusion criteria were reviewed systematically and their quality was appraised. Results. There was no Cochrane review on this subject. We found 75 articles through specific searches of PubMed and Web of Science, and hand searching. After inclusion and exclusion by full-text review, 10 articles were found for SSI, and 5 articles for delayed wound healing. The use of bDMARDs appeared to increase the rate of SSI slightly, especially in large joint-replacement surgery. Delayed wound healing was not increased by the use of bDMARDs. However, the definitions of SSI and delayed wound healing varied between the reviewed articles. Most of the articles focused on tumor necrosis factor-α inhibitors. Conclusion. bDMARDs slightly increase the relative risk of SSI but not that of delayed wound healing after orthopedic surgery and should be used with appropriate caution.

[1]  M. Tada,et al.  Delayed wound healing and postoperative surgical site infections in patients with rheumatoid arthritis treated with or without biological disease-modifying antirheumatic drugs , 2016, Clinical Rheumatology.

[2]  E. Matteson,et al.  Perioperative management of the patient with rheumatoid arthritis. , 2014, World journal of orthopedics.

[3]  K. Ikari,et al.  Recent Trends in Orthopedic Surgery Aiming to Improve Quality of Life for Those with Rheumatoid Arthritis: Data from a Large Observational Cohort , 2014, The Journal of Rheumatology.

[4]  K. Nishida,et al.  Abatacept management during the perioperative period in patients with rheumatoid arthritis: report on eight orthopaedic procedures , 2013, Modern rheumatology.

[5]  P. Tugwell,et al.  The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .

[6]  A. Mannion,et al.  Infection Risk After Orthopedic Surgery in Patients With Inflammatory Rheumatic Diseases Treated With Immunosuppressive Drugs , 2013, Arthritis care & research.

[7]  P. Ravaud,et al.  Safety of Surgery After Rituximab Therapy in 133 Patients With Rheumatoid Arthritis: Data From the AutoImmunity and Rituximab Registry , 2013, Arthritis care & research.

[8]  P. Geborek,et al.  Continuation of TNF blockade in patients with inflammatory rheumatic disease. An observational study on surgical site infections in 1,596 elective orthopedic and hand surgery procedures , 2013, Acta orthopaedica.

[9]  A. Murasawa,et al.  Analysis of perioperative clinical features and complications after orthopaedic surgery in rheumatoid arthritis patients treated with tocilizumab in a real-world setting: results from the multicentre TOcilizumab in Perioperative Period (TOPP) study , 2013, Modern rheumatology.

[10]  L. Mandl,et al.  Patterns and Associated Risk of Perioperative Use of Anti-Tumor Necrosis Factor in Patients with Rheumatoid Arthritis Undergoing Total Knee Replacement , 2013, The Journal of Rheumatology.

[11]  Takashi Nakamura,et al.  Perioperative complications in elective surgery in patients with rheumatoid arthritis treated with biologics , 2012, Modern rheumatology.

[12]  S. Momohara,et al.  Risk of postoperative complications in rheumatoid arthritis relevant to treatment with biologic agents: a report from the Committee on Arthritis of the Japanese Orthopaedic Association , 2011, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association.

[13]  W. Dixon,et al.  Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register , 2011, Annals of the rheumatic diseases.

[14]  J. Blacher,et al.  TNF alpha antagonist therapy and safety monitoring. , 2011, Joint, bone, spine : revue du rhumatisme.

[15]  G. Guyatt,et al.  GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. , 2011, Journal of clinical epidemiology.

[16]  K. Ikari,et al.  Prosthetic joint infection after total hip or knee arthroplasty in rheumatoid arthritis patients treated with nonbiologic and biologic disease-modifying antirheumatic drugs , 2011, Modern rheumatology.

[17]  K. Kanbe,et al.  Clinical factors related to the efficacy and complications of orthopedic surgery for rheumatoid arthritis with infliximab , 2011, International journal of rheumatic diseases.

[18]  A. Samanta,et al.  Should anti-TNF therapy be discontinued in rheumatoid arthritis patients undergoing elective orthopaedic surgery? A systematic review of the evidence , 2011, Rheumatology International.

[19]  P. Kiely,et al.  BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. , 2010, Rheumatology.

[20]  G. Guyatt,et al.  Effect of early surgery after hip fracture on mortality and complications: systematic review and meta-analysis , 2010, Canadian Medical Association Journal.

[21]  M. Dougados,et al.  Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study , 2010, Arthritis research & therapy.

[22]  K. Ikari,et al.  Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-alpha blockers: perioperative interruption of tumour necrosis factor-alpha blockers decreases complications? , 2010, Rheumatology.

[23]  A. Kaneko,et al.  Influences of anti-tumour necrosis factor agents on postoperative recovery in patients with rheumatoid arthritis , 2010, Clinical Rheumatology.

[24]  H. Yoshikawa,et al.  Laboratory and febrile features after joint surgery in patients with rheumatoid arthritis treated with tocilizumab , 2008, Annals of the rheumatic diseases.

[25]  W. Bamlet,et al.  Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis. , 2008, Arthritis and rheumatism.

[26]  D. Pappas,et al.  Do antitumor necrosis factor agents increase the risk of postoperative orthopedic infections? , 2008, Current opinion in rheumatology.

[27]  Jeffrey R Curtis,et al.  American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. , 2008, Arthritis and rheumatism.

[28]  S. Corrao,et al.  Surgery during etanercept therapy in patients with rheumatoid arthritis: is it time to follow patient preferences? , 2008, Internal and emergency medicine.

[29]  M. Dougados,et al.  Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers. , 2007, Clinical and experimental rheumatology.

[30]  A. Wymenga,et al.  Risk Factors for Surgical Site Infections and Other Complications in Elective Surgery in Patients with Rheumatoid Arthritis with Special Attention for Anti-Tumor Necrosis Factor: A Large Retrospective Study , 2008 .

[31]  D. Wendling.  Surgery in rheumatoid arthritis patients under anti-TNF-α therapy: what is the risk? , 2007, Clinical Rheumatology.

[32]  D. Wendling.  Surgery in rheumatoid arthritis patients under anti-TNF-alpha therapy: what is the risk? , 2007, Clinical rheumatology.

[33]  K. Fontaine,et al.  Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[34]  D. Wendling,et al.  Surgery in patients receiving anti-tumour necrosis factor alpha treatment in rheumatoid arthritis: an observational study on 50 surgical procedures. , 2005, Annals of the rheumatic diseases.

[35]  M. Hayton,et al.  Tumour necrosis factor α antagonists and early postoperative complications in patients with inflammatory joint disease undergoing elective orthopaedic surgery , 2005, Annals of the rheumatic diseases.

[36]  C. Bibbo,et al.  Infectious and Healing Complications after Elective Orthopaedic Foot and Ankle Surgery during Tumor Necrosis Factor-Alpha Inhibition Therapy , 2004, Foot & ankle international.